The Risk of Myocardial Infarction in Patients with Atrial Fibrillation Taking a Direct Thrombin Inhibitor: Myths and Reality
The purpose of this review is to analyze the results of randomized clinical trials, meta-analyses of cohort and observational studies in real clinical practice on the influence of dabigatran etexilate on the risk of myocardial infarction in patients with atrial fibrillation. A pivotal RE-LY study on...
Saved in:
| Main Authors: | B. A. Tatarsky, N. V. Kazennova, D. A. Napalkov |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2020-05-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/2168 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Thrombocytopenia Induced by Direct Oral Anticoagulants: a Clinical Case and Literature Review
by: B. A. Tatarsky, et al.
Published: (2022-11-01) -
Rivaroxaban-Associated Hepatotoxicity: a Clinical Case and Literature Review
by: B. A. Tatarsky, et al.
Published: (2019-11-01) -
Control Of Anticoagulation Therapy in Atrial Fibrillation (COAT-AF Study) in Real Clinical Practice
by: A. A. Zarudsky, et al.
Published: (2020-03-01) -
Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation in Real Clinical Practice: in Appropriate Dose Reductions
by: V. A. Ionin, et al.
Published: (2021-05-01) -
Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Renal Dysfunction
by: Z. D. Kobalava, et al.
Published: (2021-03-01)